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Abstract: The relationship between corneal arcus (arcus senilis)
and mortality from coronary heart disease (CHD) and cardiovascular
disease (CVD) is examined in a prospective study of White men (n
= 3,930) and women non-hormone users (n = 2,139), ages 30-69,
followed for an average of 8.4 years as part of the Lipid Research
Clinics Mortality Follow-up Study. After excluding those with
clinically manifest CHD at baseline, corneal arcus was strongly
associated with CHD and CVD mortality only in hyperlipidemic men
ages 3049 years, for whom the relative risk for CHD and CVD death
Introduction
Corneal arcus is an extracellular lipid infiltration of the
peripheral cornea. It appears as a yellowish-white ring
around the cornea, and is separated from the limbus by a 0.3
to 1 mm lucid zone. -4 These deposits consist mainly of
cholesterol, cholesterol esters, phospholipids, and triglyc-
erides.1.5 Corneal arcus has been described in children,3.6 but
it is more prevalent among older people and therefore has
been often called arcus senilis.1-6 It occurs more often among
Blacks than Whites4.6.7 and tends to appear earlier in life in
Blacks than in Whites.'-4,6,7
Rifkind and Dickerson8 found an association of corneal
arcus with coronary heart disease (CHD), and pointed out
that its characteristics are similar to those of atherosclerotic
lesions: both accumulate in relatively avascular tissues, both
increase with age, and are more frequent among males. Data
from the Western Collaborative Group Study indicated an
association of corneal arcus with the incidence of coronary
heart disease in men below age 50.9 Moreover, it has been
found to be related to risk factors of CHD such as hyperlip-
idemia and to occur more often among patients with familial
dyslipoproteinemias. 1-5,6-18 However, data from several
studies showed no independent relationship between corneal
arcus and CHD and suggested that both were related to
elevated serum cholesterol levels.7,8,'2,15,17
Segal, et al,18 examined the data from the Lipid Research
Clinics (LRC) Prevalence Study, which is a major source of
information on the occurrence of hyperlipidemia in North
America, and found an independent relationship between
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was 3.7 and 4.0, respectively, after adjusting for age, total choles-
terol, HDL cholesterol, and smoking status using a Cox proportional
hazards model. Among 3049 year old males, corneal arcus appears
to be a prognostic factor for CHD, independent of its association with
hyperlipidemia in this age-group, of about the same magnitude as
other common risk factors, underscoring the usefulness of comeal
arcus as a prognostic factor to the practicing clinician. (Am J Public
Health 1990; 80:1200-1204.)
corneal arcus and the prevalence of CHD. We here report on
the relation between corneal arcus diagnosed in White
participants of the LRC Prevalence Study based on the
mortality from CHD and CVD during a mean follow-up of 8.4
years.
Methods
The methods of the Lipid Research Clinics Prevalence
Study and of the Lipid Research Clinics Mortality Follow-up
Study have been described in detail elsewhere.'9.20 In sum-
mary, the following points are relevant for the present
analysis.
Prevalence Study
The Prevalence Study was conducted in the period
1972-76 in 10 Lipid Research Clinics in the United States and
Canada. In the first survey (Visit 1), 60,502 individuals (out
of 81,926 eligibles) representing a wide ethnic, geographic,
socioeconomic, and age variation had their plasma levels of
cholesterol and triglycerides determined. A 15 percent ran-
dom sample of all Visit 1 participants, plus all those with high
plasma cholesterol or triglyceride levels or who were taking
lipid-lowering medications, plus varying (by clinic) propor-
tions of those with borderline elevation in cholesterol or
triglyceride, were invited for a more extensive examination
(Visit 2). See Appendix for the definition of "high" and
"borderline elevated." Overall, 85 percent of the 12,595
persons eligible for Visit 2 were actually examined. The data
used in this analysis, except for a Visit 1 hyperlipidemia
variable, were obtained at Visit 2.
Foliow-up Mortality Study
All men and women who were at least 30 years old at
Visit 2 had their vital status determined annually from 1977
through 1983. Mean follow-up was 8.4 years, with a range of
5.7 to 9.9 years. In case of death, cause was classified as
coronary heart disease (CHD), cardiovascular disease
(CVD), or due to other causes, using standard criteria.20 For
deaths suspected of being caused by CVD, the cases were
reviewed by a panel ofcardiologists. They analyzed the death
certificate and information obtained from the next-of-kin and
from hospitalization records if the person was hospitalized
within 30 days prior to death, or from the personal physician
if there had been no hospitalization within 30 days prior to
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death. Vital status is known for over 99.6 percent of the
participants.
Exclsions
Excluded from all CVD analysis were participants with
possible or definite CHD at baseline, according to the
presence of one of the following: angina pectoris diagnosed
by the Rose Questionnaire2l or during the treadmill test; use
of angina medications, antiarrhythmics, digitalis or propran-
olol; exclusion from the treadmill test because of congestive
heart failure, R-on-T type premature ventricular contraction,
ventricular tachycardia, parasystolic focus, atrial flutter or
atrial fibrillation; or resting ECG evidence of diagnostic or
equivocal myocardial infarction.22 Female users of estrogens
or progestogens were excluded because of the small number
who had corneal arcus. Black participants were excluded
because of small numbers. Individuals invited to Visit 2
because of borderline hyperlipidemia were also excluded for
statistical reasons, as explained below, as were individuals
invited solely because of use of lipid-lowering medication.
Finally, those with nonfasting (<12 hours) or missing lipid
values and pregnant women were excluded from the analysis.
Corneal Arcus Diagnosis
The interviewers were trained to identify corneal arcus
in the Visit 2 using a uniform protocol.23,24 They stood in front
of the participants so that their eyes were at the same level
during the examination, which was usually done in natural
(rather than artificial) light, the source of which was tangen-
tial to the eye. The upper and lower poles of the eyes were
examined. Interviewers were directed to look for a whitish
fatty material at the periphery of the cornea. The corneo-
scleral junction had to be observable for a diagnosis of
corneal arcus to be made. For these analyses only positive
answers were regarded as indicative of corneal arcus and an
"uncertain" response was considered as negative.
Laboratory Methods
A detailed description of the laboratory processing
procedures is provided in the LRC Program Laboratory
Methods Manual25 and reviewed elsewhere.26
Statistical Methods
Visit 2 sample data are analyzed to draw inferences
about a population like that of Visit 1. In order to account in
analysis for the sampling scheme, the data are treated as a
stratified random sample, with two strata: hyperlipidemics,
all of whom were invited to Visit 2, and normolipidemics
(including borderline hyperlipidemics), 15 percent of whom
were invited to Visit 2. For simplification, the oversampling
of borderline hyperlipidemics and of users of lipid-lowering
medication were excluded. It should be emphasized that
borderline hyperlipidemics were not in general excluded, but
only the oversampling invited to Visit 2. Because of the
higher proportion of hyperlipidemics in the sample relative to
the population, weighting techniques were used in the esti-
mation of overall population parameters.
CHD and CVD mortality rates (deaths per 1,000 person-
years of follow-up) were calculated for corneal arcus cases
and non-cases, for each age/sex group, by lipid strata and
weighted across lipid strata. Confidence intervals or tests of
statistical significance are not given for these descriptive
statistics, but rather are reserved for the models' fit. Age
groups are 30-49 and 50-69. Similar mortality rates were also
calculated with respect to other possible prognostic factors
besides corneal arcus. These factors are given below, along
with cutpoints which define the categories (greater than or
equal to versus less than cutpoint) for which mortality rates
were calculated:
* Serum cholesterol level (240 mg/dl).
* Fasting serum triglyceride level (250 mg/dl).
* Low density lipoprotein (LDL) cholesterol level (160
mg/dl).
* High density lipoprotein (HDL) cholesterol level (40
mg/dl).
* Body mass index (BMI) (30 kg/m2).
* Smoking status (current versus ex- or nonsmoker).
* Family history of coronary heart disease (either at
least one parent died of CHD or experienced angina
before the age of 60 or at least one sibling died ofCHD
before the age of 60).
* Graded exercise test (positive ECG showed a signif-
icant ST elevation or depression or a significant
change in the ST integral value-for details see Gor-
don, et a127).
* Ischemia on resting ECG excluding myocardial infarc-
tion (either evidence of left ventricular hypertrophy or
other significant ischemia; Minnesota codes 3.1-3.3
with 4.1-4.3 or 1-3-1 through 1-3-6, or 2.1, 4.1, 4.2, 5. 1,
5.2, 6.1, 8.1, or 8.2).
In considering the effects of possible confounding vari-
ables on the relation in males aged 30-49 between corneal
arcus and CHD and CVD mortality, survival models were fit,
by lipid sampling stratum, using Cox proportional hazards
models. In addition to arcus status, survival status and
baseline age, the following baseline variables were consid-
ered: continuous [total cholesterol, LDL cholesterol, HDL
cholesterol, alcohol consumption (g/day), body mass index
(kg/m2), systolic blood pressure, triglyceride]; dichotomous
[family history ofCHD (yes = 1, no = 0), smoking (yes = 1,
no = 0)]. These variables were added one at a time to the
"basic" model, with survival status the dependent variable
and corneal arcus and age independent variables, and dis-
carded if the corneal arcus survival association was not
changed by their inclusion.
Results
For men free of coronary heart disease at baseline,
stratified by two age groups and by lipid sampling strata, the
prevalence of corneal arcus, the total follow-up time, the
mortality rates from CHD and the relative risk are presented
in Table 1. In addition, results are given for the two sampling
strata combined, with the stratum-specific results weighted to
yield estimates of mortality rates for the Visit 1 population.
A high relative risk ofCHD mortality was associated with the
diagnosis of corneal arcus among hyperlipidemic men under
50 years of age but not among older men. Table 2 shows the
same trend when mortality from CVD is considered instead
of CHD.
In female non-hormone users, the low prevalence of
corneal arcus and the small number ofCHD and CVD events
preclude any kind of analysis in the younger age group; in the
older group, where its prevalence and the number of events
increase, the same lack ofpredictive value for CHD and CVD
mortality is observed as in the older men (data available on
request to authors).
The proportional hazards models of time to CHD or
CVD death (Table 3) show that corneal arcus is an indepen-
dent prognostic factor for mortality from CHD or CVD in
men ages 30-49 years in the hyperlipidemic sampling stratum;
for normolipidemic younger men its presence does not appear
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TABLE 1-Estimated CHD Mortality Rates (deaths per 1000 person-years of follow-up) by Age Group and
Comeal Arcus Status, Excluding Those with Prior Manifstations of CHD: Males
Total
Follow-up Estimated
Corneal Number Time CHD Estimated
Sampling Arcus CHD (person- Mortality Relative
Age (years) Stratum Status N Deaths years) Rate Risk
30-49 Hyperlipidemic No 1315 10 11237.6 0.89 6.7
Yes 85 4 675.1 5.93
Normolipidemic No 1202 8 10339.5 0.77 3.4
Yes 46 1 377 2.65
Total* No 2517 18 21577.1 0.79 4.7
Yes 131 5 1052.6 3.74
50-69 Hyperlipidemic No 311 13 2504.2 5.19 0.0
Yes 68 0 583.1 0.00
Normolipidemic No 597 18 5031.9 3.58 0.9
Yes 115 3 947.5 3.17
Total* No 908 31 7536.16 3.64 0.8
Yes 183 3 1530.6 2.99
'Mortality rates weighted across sampling strata.
TABLE 2-Estimated CVD Mortality Rates (deaths per 1000 person-years of follow-up) by Age Group and
Comeal Arcus Status, Excluding Those with Prior Manietations of CHD: Males
Total
Follow-up Estimated
Corneal Number lime CHD Estimated
Sampling Arcus CHD (person- Mortality Relative
Age (years) Stratum Status N Deaths years) Rate Risk
30-49 Hyperlipidemic No 1315 13 11237.6 1.16 6.4
Yes 85 5 675.1 7.41
Normolipidemic No 1202 14 10339.5 1.35 2.0
Yes 46 1 377 2.65
Total* No 2517 27 21577.1 1.32 3.2
Yes 131 6 1052.1 4.23
50-69 Hyperlipidemic No 311 22 2504.2 8.79 0.0
Yes 68 0 583.1 0.00
Normolipidemic No 597 26 5031.9 5.17 1.0
Yes 115 5 947.5 5.28
Total* No 908 48 7536.2 5.31 0.9
Yes 183 5 1530.6 4.98
'Mortality rates weighted across sampling strata.
TABLE 3-Estimated CHD and CVD Hazard Ratio, Comparing Subjects
with Comeal Arcus to Those Without; Adjusted for Age, Total
Cholesterol, HDL-C, and Smoking*, Men Aged 30-49 Years
(95 Percent (95 Percent
CHD Hazard Confidence CVD Hazard Confidence
Lipid Stratum Ratio Interval) Ratio Interval)
Hyperlipidemic 3.7 (0.9,14.7) 4.0 (1.2,12.9)
Normolipidemic 2.2 (0.3,20.1) 1.3 (0.2,10.4)
'LDL-cholesterol, alcohol consumpbon, BMI, systolic blood pressure, and triglyceride
were also considered, but had no effect on the C.A./survival association, so were discarded.
to be ofthe same importance. The covariates included are age
and those whose inclusion in the model substantially modified
the estimates of relative hazard ofCHD or CVD mortality as
related to corneal arcus. These covariates are total choles-
terol, HDL-cholesterol, and smoking. With or without these
additional covariates the relative hazards are similar for
normolipidemics, but for hyperlipidemics the relative haz-
ards adjusted for age alone are about 1.6 times those for
models presented in Table 3.
The relative risk of the diagnosis of corneal arcus in the
30-49 year old male group is compared in Table 4 to that of
other possible risk factors. As can be seen there, comeal
arcus appears to be at least as statistically strong a prognostic
factor for CHD as obesity, hypo-HDL, ischemia on resting
ECG, hypertriglyceridemia and family history of CHD, and
not very different in magnitude from the relative risk from
smoking habit, hypertension, hyper-LDL, and hypercholes-
terolemia. Details concerning this relation are given in Segal,
et al.18
Discussion
In men under 50 years of age, corneal arcus has been
shown in a prospective study to be a predictor of CHD
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TABLE 4-Estimated Mortality Rates (per 1000 person-years) and Relative Risks of Death from CHD In Asymptomatic Men Aged 30-49 Years, by CHD Risk
Factor Status
Hyperlipidemic Stratum Normolipidemic Stratum Population Estimates*
Death Relative Death Relative Death Relative
Risk Factor Status Rate Risk Rate Risk Rate Risk
Comeal Arcus Yes 5.93 6.66t 2.65 3.44 3.74 4.73
No 0.89 0.77 0.79
Current Smoker Yes 2.00 4.26tt 1.72 5.73tt 1.78 5.56tt
No 0.47 0.30 0.32
Quetelet Index .30 1.27 1.55 0.96 - 1.00 3.57
<30 0.82 - 0.28
Hypertensive Yes 1.96 2.33 2.68 7.66tt 2.48 5.90tt
No 0.84 0.35 0.42
LDL-C Level .160 1.84 3.61tt 3.33 9.79tt 2.39 6.83tt
<160 0.51 0.34 0.35
HDL-C Level <40 1.76 2.71t 1.66 3.95t 1.68 3.73tt
.40 0.65 0.42 0.45
Ischemia on Exercise ECG Present 9.79 9.79 10.00 14.29 9.94 13.25
Absent 1.00 0.70 0.75
Ischemia on Resting ECG Present 7.64 7.64 2.15 2.56 2.70 3.14
Absent 1.00 0.84 0.86
Cholesterol Level .240 2.19 - 5.21 12.71tt 2.59 6.64
<240 - 0.41 0.39
Triglyceride Level .250 1.73 1.94 2.37 3.04 1.78 2.25
<250 0.89 0.78 0.79
Family History of CHD Present 2.17 2.44 0.96 1.17 1.21 1.46
Absent 0.89 0.82 0.83
*Weighted across sampling strata.
tO-05 < p < 0.10, two-sided test.
ttO.01 < p < 0.05, two-sided test.
mortality, independent of presence of hyperlipidemia, and a
stronger predictor for hyperlipidemics. Above the age of 50
its diagnosis does not appear to be positively related to the
subsequent manifestation of a fatal CHD event. These
findings help to clarify previous discussion about this
relation,7'28 confirming the observations made in retrospec-
tive,8,29 cross-sectional,18,30 and prospective studies.9 They
are in agreement with the interpretation that corneal arcus
and coronary atherosclerosis share common determinants in
young men, while local factors are more important for its
occurrence in older persons.8"12
The findings in women confirm the low prevalence of
corneal arcus in the young age group,30.3' which with the low
mortality rates rules out the possibility of drawing conclu-
sions about its relation to CHD and CVD mortality. In the
older group, where the prevalence of corneal arcus and the
mortality rate increase, there is the same lack of relation
observed in older men.
The ability to detect patients at high risk of CHD has
been of continuous concern, considering the frequent pre-
sentation of the disease as sudden death32 and its devastating
consequences, especially in the families of young men. The
magnitude of the comeal arcus risk in this age group com-
pared to other usual screening tests (Table 4) highlights the
utility of this simple and inexpensive tool as a prognostic
factor and reinforces the importance of its diagnosis during
the physical examination. This is noteworthy, considering
that it had lower prevalence in the baseline of this population-
based cohort than in some studies which used hospitalized or
referred patients. The fact that, in this study, corneal arcus
was detected only by a single examination, without the use of
slit lamp, could have resulted in some misclassification.'7
However, such misclassification would be independent of
either lipid status or later CHD mortality, so would only bias
our results toward the null, that is, toward finding no
association between it and CHD mortality. The association
between corneal arcus and hyperlipidemia alone would
suggest evaluation of the lipid profile of young men with
corneal arcus. The findings in this paper indicate that it also
may be prudent to suggest that all young patients with corneal
arcus should undergo a detailed evaluation of their other
CVD risk factors.
APPENDIX
Age-Specific Cutpolnts Used for Selecting Participants for Visit 2
Cholesterol (mg/dl)* Triglyceride (mg/dl)**
Borderline Elevated Borderline Elevated
Age Group Cutpoint Cutpoint Cutpoint Cutpoint
30-39 220 240 150 250
40-49 225 260 150 300
50-59 245 280 150 300
60+ 245 280 150 300
'Conversion factor to SI Units (mmol/L): 0.02586
-Conversion factor to SI Units (mmol/L): 0.1129
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